Latest News - Sun Pharmaceutical Industries Ltd

Tuesday, October 23, 2018

Ilumya Now Available for Moderate-to-Severe Plaque Psoriasis

Ilumya™ (tildrakizumab-asmn) 100mg/mL from Sun Pharmaceutical Industries Ltd. is now available in the United States. Ilumya is an injectable interleukin-23 (IL-23) inhibitor approved by the FDA …

Read the full story

Wednesday, March 21, 2018

Sun Pharma: FDA Approves Ilumya for Adult Psoriasis

The FDA has approved Ilumya™ (tildrakizumab-asmn) from Sun Pharma for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Il…

Read the full story

Monday, October 23, 2017

Sun Dermatology Launches Absorica Tracker App to Help Patients Track Progress

Sun Pharma launched an Absorica Tracker App to help patients get the most out of their treatment. The easy-to-use interface is designed to help users to monitor their progress with Absorica (isotretin…

Read the full story

Wednesday, September 20, 2017

New Label Reflects Sustained Response for Sun Pharma’s Odomzo in BCC

Sun Pharma’s new Odomzo® (Sonidegib) label incorporates long-term data showing sustained duration of response of 26 months in treatment of locally advanced basal cell carcinoma. Odom…

Read the full story

Wednesday, July 05, 2017

Samsung Biologics to Manufacture Sun Pharma’s Tildrakizumab for Psoriasis

Sun Pharmaceutical Industries just inked a long-term agreement with South Korea’s Samsung BioLogics to manufacture Tildrakizumab for psoriasis. The investigational IL-23p19 inhibitor drug is …

Read the full story

Wednesday, June 07, 2017

Tildrakizumab Performs Well in Two Phase 3 Psoriasis Studies

Two Phase 3 trials show that tildrakizumab is efficacious and well-tolerated in patients with moderate-to-severe chronic plaque psoriasis. Specifically more than 60 percent of all patients who rece…

Read the full story

Wednesday, May 24, 2017

Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application For Tildrakizumab

The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Sun Pharma’s tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the tre…

Read the full story

Thursday, March 02, 2017

Sun Pharma to Present Data from Tildrakizumab Clinical Development Program at 2017 AAD Meeting

Sun Pharmaceutical Industries Ltd will present several new analyses from Phase-1 and the pivotal Phase-3 clinical trials (reSURFACE 1 and 2) of tildrakizumab, an investigational IL-23p19 inhibitor bei…

Read the full story

Tuesday, January 24, 2017

Sun Pharma Introduces Leave Acne Behind Patient Initiative

Sun Pharma introudced a new initiative -- “Leave Acne Behind™" -- to educate patients and create awareness of severe recalcitrant nodular acne (SRNA). Sun Pharma reports that out o…

Read the full story